Physician profile
Tyler Vines
NPI 1730618729
$1,516.06
in general payments reported to CMS, 2019-2025
28 companies · $198 in 2025
The $198 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $137 · 2021: $89.78 · 2022: $311 · 2023: $314 · 2024: $79.92 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $190.62 | 2022-2025 | Botox, Ubrelvy, Qulipta |
| Genentech USA, INC. | $149.35 | 2019 | |
| Abbott Laboratories | $135.50 | 2022 | |
| Greenwich Biosciences, INC. | $128.62 | 2019-2021 | |
| Lundbeck LLC | $90.36 | 2023-2025 | Vyepti |
| Allergan, INC. | $85.37 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.76 | 2020-2024 | Hyqvia |
| Pfizer INC. | $69.04 | 2019-2025 | |
| Boston Scientific Corporation | $59.62 | 2023 | |
| Supernus Pharmaceuticals, INC. | $58.05 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $54.09 | 2023 | Rexulti |
| Csl Behring | $47.93 | 2019 | |
| Eisai INC. | $36.26 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $35.05 | 2022 | |
| Tg Therapeutics, INC. | $34.95 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $34.08 | 2021 | |
| Novartis Pharmaceuticals Corporation | $25.79 | 2022 | |
| Portola Pharmaceuticals, LLC | $25.45 | 2019 | |
| Amneal Pharmaceuticals LLC | $24.83 | 2025 | Crexont |
| Impel Pharmaceuticals LLC | $19.95 | 2025 | Trudhesa |
| Neurocrine Biosciences, INC. | $19.22 | 2022 | |
| Livanova USA, INC. | $18.97 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.47 | 2025 | Austedo Xr |
| Lilly USA, LLC | $18.46 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.83 | 2023 | Soliris |
| Amgen INC. | $16.69 | 2022 | |
| Impel Pharmaceuticals INC. | $16.18 | 2023 | Trudhesa |
| Averitas Pharma INC. | $15.57 | 2024 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Vines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.